Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: A randomised, double-blind, placebo-controlled, phase I, first-in-human study

Gerd Rüdiger Burmester, Eugen Feist, Matthew A. Sleeman, Bing Wang, Barbara White, Fabio Magrini

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: A randomised, double-blind, placebo-controlled, phase I, first-in-human study'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds